<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="95696"><DrugName>LUNAR-CF</DrugName><DrugSynonyms><Name><Value>LUNAR-CF</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CFTR gene therapy (lipid nanoparticles, cystic fibrosis), Arcturus Therapeutics</Value></Name></DrugSynonyms><CompanyOriginator id="1084485">Arcturus Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company id="1084485">Arcturus Therapeutics Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1084485" type="Company"><TargetEntity id="5039650094" type="organizationId">Arcturus Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="88" type="ciIndication"><TargetEntity id="E84" type="ICD10"/><TargetEntity id="10011762" type="MEDDRA"/><TargetEntity id="D003550" type="MeSH"/><TargetEntity id="586" type="ORPHANET"/><TargetEntity id="-1447400656" type="omicsDisease"/><TargetEntity id="288" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="88">Cystic fibrosis</Indication></IndicationsPrimary><ActionsPrimary><Action id="17767">CFTR gene stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="4789">Lipid based gene therapy</Action></ActionsSecondary><Technologies><Technology id="142">Liposome formulation</Technology><Technology id="1668">Nanoparticle formulation</Technology><Technology id="103">Oligonucleotide</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="617">Aerosol formulation inhalant</Technology></Technologies><LastModificationDate>2019-06-13T15:52:23.000Z</LastModificationDate><ChangeDateLast>2019-05-15T00:00:00.000Z</ChangeDateLast><AddedDate>2016-11-03T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1084485" linkType="Company"&gt;Arcturus Therapeutics&lt;/ulink&gt; is investigating  LUNAR-CF, a cystic fibrosis transmembrane conductance regulator (CFTR) mRNA therapeutic, developed using  its Lipid-enabled and Unlocked Nucleic Acid modified RNA (LUNAR) nanoparticle delivery technology, for the potential nebulizer-based treatment of   cystic fibrosis [&lt;ulink linkID="2049293" linkType="Reference"&gt;2049293&lt;/ulink&gt;], [&lt;ulink linkID="1639619" linkType="Reference"&gt;1639619&lt;/ulink&gt;], [&lt;ulink linkID="1639784" linkType="Reference"&gt;1639784&lt;/ulink&gt;]. In October 2016, the  drug was listed as being in preclinical stage on the company's pipeline  [&lt;ulink linkID="1807068" linkType="Reference"&gt;1807068&lt;/ulink&gt;]; in April 2019, this was still the case [&lt;ulink linkID="2145153" linkType="Reference"&gt;2145153&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2017, &lt;ulink linkID="22534" linkType="Company"&gt;Cystic Fibrosis Foundation Therapeutics&lt;/ulink&gt; (CFFT) awarded a grant to  Arcturus  worth up to $3M for the discovery and development of LUNAR-CF [&lt;ulink linkID="1931597" linkType="Reference"&gt;1931597&lt;/ulink&gt;]. In July 2018, Arcturus  achieved  key milestones related to the agreement [&lt;ulink linkID="2056426" linkType="Reference"&gt;2056426&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In February 2019, the EMA's COMP recommended granting Orphan designation to codon-optimized human CFTR mRNA complexed with lipid-based nanoparticles for treatment of cystic fibrosis [&lt;ulink linkID="2127157" linkType="Reference"&gt;2127157&lt;/ulink&gt;]; in April 29019, the Orphan designation was granted [&lt;ulink linkID="2151157" linkType="Reference"&gt;2151157&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2016, the  drug was listed as being in preclinical stage in the company's pipeline [&lt;ulink linkID="1807068" linkType="Reference"&gt;1807068&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2018, the lead CFTR mRNA had been shown to have improved functional activity and longer duration of protein expression compared with a reference CFTR mRNA in cell-based assays [&lt;ulink linkID="2068467" linkType="Reference"&gt;2068467&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June  2018,  preclinical data were presented at the Cystic Fibrosis Foundation Research Conference in Jackson Hole, Wyoming. In a mouse model, LUNAR-CF was compatible with  nebulization and shielded the mRNA from degradation in CF sputums, thereby achieving proof-of-concept for efficient nebulized delivery into lung epithelial cells  [&lt;ulink linkID="2056426" linkType="Reference"&gt;2056426&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, preclinical data were presented at the 31st Annual North American Cystic Fibrosis Conference in Indianapolis, IN. In mouse, both intranasal and intratracheal delivery of LUNAR-CF formulated with luciferase mRNA  showed significant luciferase protein expression in lungs at 6 and 24-h time points [&lt;ulink linkID="1985910" linkType="Reference"&gt;1985910&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In March 2015, the program was listed as being in discovery stage [&lt;ulink linkID="1639619" linkType="Reference"&gt;1639619&lt;/ulink&gt;], [&lt;ulink linkID="1639784" linkType="Reference"&gt;1639784&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;The drug has been designed to deliver  normal CFTR mRNA  into airway epithelial cells of the lung, which allows these cells to generate functional CFTR [&lt;ulink linkID="2145153" linkType="Reference"&gt;2145153&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1084485">Arcturus Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2019-02-19T00:00:00.000Z</StatusDate><Source id="2127157" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1084485">Arcturus Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2016-10-14T00:00:00.000Z</StatusDate><Source id="1807068" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1084485">Arcturus Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2015-01-07T00:00:00.000Z</StatusDate><Source id="1639784" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1084485">Arcturus Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-04-01T00:00:00.000Z</MileStoneDate><Source id="2151157" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1084485">Arcturus Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2019-02-21T00:00:00.000Z</MileStoneDate><Source id="2127157" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="GTGT-02413"><Name>CFTR gene</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1084485">Arcturus Therapeutics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22534">Cystic Fibrosis Foundation Therapeutics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="240324" title="CFFT to award Arcturus funding to develop LUNAR-CF for cystic fibrosis "/></Deals><PatentFamilies><PatentFamily id="4293109" number="WO-2018222890" title="Synthesis and structure of high potency RNA therapeutics"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arcturus Therapeutics Inc" id="1084485"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>